• No formal drug interaction studies have been conducted
  • Sirolimus is known to be a substrate for both CYP3A4 and P-gp; inducers of CYP3A4 and P-gp may decrease sirolimus concentrations whereas inhibitors of CYP3A4 and P-gp may increase sirolimus concentrations
  • Avoid concomitant use of FYARRO with grapefruit and grapefruit juice
Drug interaction Recommendation
Strong inducers or inhibitors of CYP3A4 (including grapefruit and grapefruit juice) and/or P-gp Concomitant use should be avoided
Moderate or weak inhibitor of CYP3A4 and/or P-gp FYARRO dose reduction to 56 mg/m2 per dose should be considered
Moderate or weak inducers of CYP3A4 May result in decreased efficacy of FYARRO